Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.45 |
| ▸ | P2RY12 | Q9H244 | 14/20 | 0.41 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.39 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.39 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.39 |
| ▸ | AHCY | P23526 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19927246 | 1.00 | PRMT6 (0.45) | PRMT6P2RY12P2RY2P2RY1P2RY6 | |
| SCHEMBL19146386 | 0.91 | PRMT6 (0.47) | PRMT6P2RY12 | |
| SCHEMBL22206837 | 0.90 | PRMT6 (0.49) | PRMT6P2RY12P2RY2P2RY1P2RY6 | |
| SCHEMBL30445813 | 0.90 | PRMT6 (0.49) | PRMT6P2RY12P2RY2P2RY1P2RY6 | |
| SCHEMBL19927301 | 0.89 | PRMT6 (0.46) | PRMT6P2RY12P2RY2P2RY1P2RY6 | |
| SCHEMBL19927469 | 0.88 | PRMT6 (0.49) | PRMT6P2RY12P2RY2P2RY1P2RY6 | |
| SCHEMBL19927404 | 0.85 | AHCY (0.53) | P2RY12AHCY | |
| SCHEMBL19927403 | 0.85 | AHCY (0.53) | P2RY12AHCY | |
| SCHEMBL25496498 | 0.84 | PRMT6 (0.48) | PRMT6P2RY12P2RY2P2RY1P2RY6 | |
| SCHEMBL25496516 | 0.84 | PRMT6 (0.48) | PRMT6P2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190345191-A1 | CYCLIC DINUCLEOTIDE ANALOGS FOR TREATING CONDITIONS ASSOCIATED WITH STING (STIMULATOR OF INTERFERON GENES) ACTIVITY | INNATE TUMOR IMMUNITY INC (US) | 2019-11-14 | — | — | US | disclosed |
| WO-2018045204-A1 | CYCLIC DINUCLEOTIDE ANALOGS FOR TREATING CONDITIONS ASSOCIATED WITH STING (STIMULATOR OF INTERFERON GENES) ACTIVITY | IFM THERAPEUTICS, INC (US) | 2018-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190345191-A1 | CYCLIC DINUCLEOTIDE ANALOGS FOR TREATING CONDITIONS ASSOCIATED WITH STING (STIMULATOR OF INTERFERON GENES) ACTIVITY | STING1, CGAS, IRF3 | PRMT6 3041/4885P2RY12 235/4885P2RY2 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.